FLT3 and acute myeloid leukemia: In addition, alemtuzumab showed the ADCC in MOLM-13 cells, a human AML cell line harboring FLT3-ITD, which was slightly resistant to quizartinib compared with MOLM-14 cells which were also a human AML cell line with FLT3-ITD (Supplementary Fig. S7a–c).